Physician profile

Terry B Kim

Optometrist · Aspen Hill, MD

NPI 1265961627

$1,439.08

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$906.09
Travel and Lodging$253.57

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alcon Vision LLC $816.00 2020-2023 Air Optix, Dailies Total1 Multifocal, Dailies Aqua Comfort Plus
Coopervision INC. $207.64 2022-2024 Myday Contact Lens
Alcon Research LLC $138.10 2023 Clareon, Acrysof Iq Vivity
Bausch & Lomb Americas INC. $124.29 2023 Biotrue One Day, Biotrue
Novartis Pharmaceuticals Corporation $121.57 2022
Johnson & Johnson Vision Care, INC. $31.48 2021-2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Terry B Kim

$1,439.08

in general payments reported 2019-2025

Years
2020-2024
Top company
Alcon Vision LLC

https://glasscript.com/doctor/4131962/terry-b-kim

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.